NCT07118449View on ClinicalTrials.gov

Epicardial Delivery of XC001 Gene Therapy to Promote Angiogenesis in CAD Patients Undergoing Treatment With CABG

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

116

Participants

Timeline

Start Date

August 27, 2025

Primary Completion Date

December 30, 2026

Study Completion Date

June 30, 2027

Conditions
Coronary Artery Disease (CAD)
Interventions
DRUG

XC001

22 injections will be administered at the end of the CABG procedure as a one time treatment.

DRUG

A195/placebo

22 injections of A195/placebo will be administered at the end of the CABG procedure.

Trial Locations (1)

45202

Christ Hospital, Cincinnati

All Listed Sponsors
lead

XyloCor Therapeutics, Inc.

INDUSTRY